Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424567 · ClinicalTrials.gov registry record · Phase 1
Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.
A Phase 1 study, sponsored by Vericel Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00424567 is a Phase 1 study that was terminated before completion, run by Vericel Corporation. The registered enrollment target is 36 participants.
The verdict
NCT00424567, a Phase 1 study, was terminated before completion, sponsored by Vericel Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this multi-center study is to obtain clinical data to substantiate that Aastrom TRC autologous bone marrow cells will regenerate bone in patients with established (appendicular skeletal) non union fractures, when used with one of the commonly employed commercially available allograft chip matrices.
Interventions
- PROCEDURE Fracture surgery
- DRUG Cultured Bone Marrow Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424567
The ClinicalTrials.gov registry entry for NCT00424567 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vericel Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fracture surgery is the first listed.
NCT00424567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424567 about?
NCT00424567 is a clinical study titled "Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.". The purpose of this multi-center study is to obtain clinical data to substantiate that Aastrom TRC autologous bone marrow cells will regenerate bone in patients with established (appendicular skeletal) non union fractures, when used with one of the commonly employed commercially available allograft ...
What is the current status of trial NCT00424567?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2003-10. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00424567?
The interventions under investigation include: Fracture surgery (PROCEDURE), Cultured Bone Marrow Tissue (DRUG).
Who is sponsoring clinical trial NCT00424567?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.